Medtronic Addresses Diabetes Care Disparities With New Equity Initiatives

The company announced new research investments and partnerships with the American Diabetes Association and the T1D Exchange to address racial disparities in treatment of diabetes.

Finding balance, equality, stability concept with libra, scale, balls or globes in realistic studio interior room, 3d rendering illustration wallpaper - Image ID: 2CFHT2P
• Source: Alany

Medtronic is taking advantage of its vast resources and network of relationships with health care providers to improve access to diabetes care in underserved communities.

More from Diabetic Care

Dexcom’s FDA Warning Letter Shows Risks Of Driving Margin As Firm Aims To Launch 15-Day Sensor

 
• By 

After switching production of coatings for its continuous glucose monitors in-house to improve supply, Dexcom ran afoul of US FDA for failing to submit a premarket notification. Firm says launch of 15-day sensor will not be delayed by the problems.

Research Finds Benefit From DME Suppliers For People Living With Diabetes

 
• By 

People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.

Dexcom Faces US FDA Warning Amid Agency Review Of 15-Day Sensor

 
• By 

Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.

Libre 3 Sensors: With Second Plant Online, Abbott Aims For Under-Penetrated ‘Intensive Insulin’ Segment

 
• By 

Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.

More from Device Area

Enovis Appoints Damien McDonald CEO, Reaffirms Q1 Guidance Amid Strategic Growth Push

 
• By 

Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.

Dexcom’s FDA Warning Letter Shows Risks Of Driving Margin As Firm Aims To Launch 15-Day Sensor

 
• By 

After switching production of coatings for its continuous glucose monitors in-house to improve supply, Dexcom ran afoul of US FDA for failing to submit a premarket notification. Firm says launch of 15-day sensor will not be delayed by the problems.